| abstract |
The present invention relates to antagonists/inhibitors of NR2F6 (nuclear orphan receptor receptor Ear2) for the treatment of a disease related to an insufficient immune response. Furthermore, pharmaceutical compositions comprising said antagonists/inhibitors of NR2F6 and a pharmaceutical carrier are comprised. In a further aspect, the present invention provides for a method for identifying immunoaugmenting agents comprising contacting a cell, tissue or a non-human animal comprising a reporter construct for NR2F6-inhibition with a candidate molecule, measuring the reporter signal and selecting a candidate molecule which alters the reporter signal. Furthermore, the present invention relates to the non-human transgenic animals or cells or tissue derived therefrom useful in the provided methods for identifying immunoaugmenting agents. In yet another aspect, the present invention relates to ligand-mediated reporter gene expression constructs, ligand displacement constructs, fluorescent cellular sensor fusion mutant constructs and ligand-induced homo- and/or heterodimer constructs useful in the provided methods for identifying immunoaugmenting agents. |